1. Introduction: How Should Korean Botulinum Toxin Products Be Evaluated?

Korean botulinum toxin type A (BoNT-A) products are manufactured by different pharmaceutical companies and supported by separate regulatory and clinical evidence programs.

The term Korean botulinum toxin describes a country of manufacture. It does not identify one pharmaceutical product, formulation, potency assay or clinical evidence base.

For example, Neuronox is manufactured by Medytox Inc., while NABOTA is manufactured by Daewoong Pharmaceutical. Both originate from the Republic of Korea, but they have distinct product identities, supporting studies and market-specific regulatory information. ［1–5］

An evidence-based evaluation should therefore begin with the exact product rather than its country of origin.

This article presents a structured framework for examining Korean botulinum toxin products through manufacturer information, approved labeling, clinical trials, study endpoints and safety data.

2. Why Country of Manufacture Is Not an Evidence Grade

Manufacturing origin is an important product-identification detail, but it does not independently establish a product's clinical efficacy, safety, duration of effect or purity.

These questions require different forms of evidence.

For instance, a product's approved indications must be established through the applicable regulatory information. Its clinical efficacy should be evaluated using studies conducted with that specific preparation. Comparative efficacy requires appropriate comparative clinical evidence.

Two products manufactured in the same country may differ in their manufacturing processes, formulations, clinical development programs and approved indications.

Country of origin should be recorded as a product fact, not used as a substitute for product-specific evidence.

3. Start With the Exact Product and Manufacturer

Before reviewing a clinical publication, establish which product was actually investigated.

The brand name, nonproprietary name, manufacturer and relevant market should be recorded wherever the information is available.

3.1 Neuronox: Medytox Inc.

Neuronox is a botulinum toxin type A product manufactured by Medytox Inc. in the Republic of Korea.

The Thai product information identifies the product and manufacturer and provides a source for checking its locally approved use and handling requirements. The source document referenced in this article was revised on April 3, 2023. ［1］

Neuronox also has published randomized clinical evidence, including a direct comparative Phase III study in glabellar lines. ［2］

3.2 NABOTA: Daewoong Pharmaceutical

NABOTA is a botulinum toxin type A product manufactured by Daewoong Pharmaceutical.

Daewoong's product information identifies its product presentations and selected approved indications by market. Published clinical literature has also evaluated Daewoong's DWP450/prabotulinumtoxinA development program. ［3–5］

Because trade names and regulatory terminology may differ across markets, the relationship between a development name, nonproprietary name and marketed product should be verified before combining evidence under a single brand heading.

Table 1. Product identity and evidence sources

Product

Manufacturer

Relevant evidence sources

Neuronox

Medytox Inc.

Thai product information and randomized clinical trials

NABOTA

Daewoong Pharmaceutical

Manufacturer product information and DWP450/prabotulinumtoxinA clinical publications

The two evidence programs should be assessed separately unless a study directly connects the products.

4. Check Regulatory Status by Jurisdiction

A product's regulatory status is specific to the jurisdiction in which it is marketed.

Approval in the Republic of Korea should not be assumed to establish identical approval in Thailand, the United States, Europe or another market.

Likewise, an indication listed in one country's product information should not automatically be transferred to another country's product description.

An appropriate regulatory review should identify the relevant market, the applicable product name, the date or version of the product information, and the approved indications and safety statements.

Table 2. Regulatory information to verify

Information

Why it matters

Brand and nonproprietary name

Confirms the exact product

Manufacturer

Establishes product identity

Jurisdiction

Identifies the relevant regulatory framework

Label revision date

Establishes which version is being cited

Approved indications

Distinguishes authorized uses from research applications

Dosing and administration

Provides product-specific requirements

Contraindications and warnings

Establishes locally applicable safety information

Storage and preparation

Supports correct product handling

Regulatory information and clinical research answer related but different questions. A published study of a particular use does not, by itself, establish that the use is approved in every jurisdiction.

5. Neuronox Clinical Evidence: What Has Been Studied?

Neuronox has published randomized clinical evidence in aesthetic and selected therapeutic settings.

One relevant study is the Phase III trial published by Lee WS and colleagues in Dermatologic Surgery in 2013. It compared a new botulinum toxin type A product with onabotulinumtoxinA for glabellar lines. ［2］

5.1 Direct Comparative Evidence in Glabellar Lines

The randomized, double-blind, active-controlled, multicenter trial included 314 participants.

At Week 4, the reported responder rates were 93.7% for Neuronox and 94.5% for onabotulinumtoxinA. The study met its prespecified non-inferiority criterion. ［2］

Table 3. Neuronox comparative Phase III study

Study characteristic

Reported information

Indication

Glabellar lines

Study design

Randomized, double-blind, active-controlled, multicenter Phase III

Participants

314

Investigational product

Neuronox

Active comparator

OnabotulinumtoxinA

Neuronox Week-4 responder rate

93.7%

Comparator Week-4 responder rate

94.5%

Statistical conclusion

Met the prespecified non-inferiority criterion

The finding supports the study's non-inferiority conclusion for the investigated population, dose, endpoint and assessment period.

It should not be interpreted as evidence of superiority or universal interchangeability.

5.2 Evidence Beyond Aesthetic Treatment

Other published randomized studies have investigated Neuronox or the Meditoxin name used in the respective publications in selected therapeutic indications.

These include essential blepharospasm, spastic equinus in children with cerebral palsy and post-stroke upper-limb spasticity.

Each study should be reviewed according to its own population, treatment regimen, endpoint and follow-up period. Therapeutic outcomes should not be combined with aesthetic responder rates as though they measure the same clinical result.

6. NABOTA Clinical Evidence: What Has Been Studied?

Daewoong's botulinum toxin development program includes published randomized studies involving DWP450/prabotulinumtoxinA in glabellar lines.

Two relevant publications are a comparative trial by Won CH and colleagues and a subsequent Phase III study by Rzany BJ and colleagues. ［4,5］

6.1 DWP450 Comparative Trial

Won CH and colleagues published a multicenter, randomized, double-blind, active-controlled study comparing DWP450 with onabotulinumtoxinA in glabellar lines. ［4］

The study provides direct comparative evidence under its specified treatment and assessment protocol.

6.2 PrabotulinumtoxinA Phase III Study

Rzany BJ and colleagues published a multicenter, randomized, double-blind, placebo-controlled, single-dose Phase III non-inferiority study comparing prabotulinumtoxinA with onabotulinumtoxinA for moderate-to-severe glabellar lines. ［5］

The study included both an active comparator and a placebo-controlled component, allowing evaluation within its predefined design.

Table 4. Selected Daewoong development-program publications

Study

Product studied

Comparator

Indication

Won et al., 2015

DWP450

OnabotulinumtoxinA

Glabellar lines

Rzany et al., 2020

PrabotulinumtoxinA

OnabotulinumtoxinA and placebo

Moderate-to-severe glabellar lines

The exact relationship between a clinical development name and the marketed product should be documented using the relevant product and regulatory information.

7. Can Neuronox and NABOTA Be Compared Directly?

Neuronox and NABOTA have separate clinical evidence programs, including published comparisons with onabotulinumtoxinA.

However, having a common comparator in different trials does not make the trials equivalent.

For example, studies may differ in participant characteristics, baseline severity, administered dose, response definitions, assessment schedules and statistical margins.

The reviewed source set does not identify a direct randomized head-to-head trial comparing Neuronox with NABOTA.

Accordingly, their individual findings can be presented side by side, but a direct comparative conclusion between the two products is not established by the cited studies alone.

Table 5. Direct and indirect evidence

Evidence type

What it can establish

Neuronox vs onabotulinumtoxinA trial

A direct comparison under the Neuronox study protocol

DWP450/prabotulinumtoxinA vs onabotulinumtoxinA trial

A direct comparison under the respective Daewoong study protocol

Comparison of separate Neuronox and Daewoong trials

A descriptive comparison of study findings, subject to methodological differences

Neuronox vs NABOTA head-to-head trial

Would provide direct evidence under a shared protocol; none was identified in the reviewed source set

8. How Should Potency Units Be Compared?

Botulinum toxin potency units are product-specific.

The numerical units of one product should not be assumed to represent the same biological potency or clinical dose as an equal number of units of another preparation.

Similarly, a dose ratio used in a clinical trial describes the treatment regimen investigated in that study.

It should not automatically become a conversion formula for other indications, treatment regions or patient populations.

When presenting clinical evidence, the product name and administered dose should remain together so that the numerical result is not separated from its context.

9. What Clinical Outcomes Should Be Evaluated?

A complete evidence review should consider more than whether a study reported a positive primary efficacy result.

The relevant outcomes depend on the indication and research question.

For aesthetic studies, outcomes may include investigator-assessed wrinkle severity, participant-assessed improvement and responder rates at defined follow-up visits.

Therapeutic studies may use muscle tone, functional assessments or other indication-specific measures.

Safety data should be evaluated separately from efficacy.

Table 6. Evidence dimensions for Korean BoNT-A products

Dimension

Questions to examine

Efficacy

What was the primary endpoint, and how was it measured?

Study design

Was the trial randomized, blinded or comparator-controlled?

Population

Who was included, and what was the baseline condition?

Dose

What product-specific dose was administered?

Follow-up

When were outcomes assessed?

Safety

What adverse events were collected and reported?

Statistical analysis

Was the study designed for superiority, non-inferiority or equivalence?

Disclosures

Who funded the study, and what conflicts were reported?

The strength of a claim depends on the evidence supporting that specific claim, not simply on the total number of publications associated with a product.

10. Why Safety Evidence Requires Product-Specific Review

Safety is influenced by the product, indication, dose, administration technique and patient-specific factors.

Clinical trials provide safety information for the population and treatment regimen investigated. They may not be sufficiently large or long to identify every uncommon or delayed adverse event.

An efficacy result from a non-inferiority study also does not establish identical safety profiles across products.

Product-specific contraindications, warnings, preparation requirements and adverse-event information should therefore be obtained from the current locally approved product information.

Funding and author conflict-of-interest disclosures should remain visible when clinical studies are summarized.

11. Frequently Asked Questions

Are all Korean botulinum toxin products the same?

No. Products manufactured in the Republic of Korea may have different manufacturers, formulations, potency assays, trade names, clinical evidence programs and approved indications.

Are Neuronox and NABOTA made by the same company?

No. Neuronox is manufactured by Medytox Inc., while NABOTA is manufactured by Daewoong Pharmaceutical. ［1,3］

Does Korean manufacture establish a particular efficacy or safety profile?

No. Efficacy and safety must be evaluated using evidence relevant to the exact product, indication, dose and population.

Does Neuronox have randomized clinical evidence?

Yes. Published evidence includes a randomized Phase III comparison with onabotulinumtoxinA in glabellar lines. ［2］

Does NABOTA have randomized clinical evidence?

Daewoong's DWP450/prabotulinumtoxinA development program includes randomized comparative studies in glabellar lines. The applicable product naming relationship should be verified for the intended market. ［3–5］

Can results from separate Neuronox and NABOTA studies establish which product performs better?

Separate studies may use different protocols, populations and endpoints. A direct comparative conclusion requires evidence and an analysis appropriate to that specific question.

What information should be checked first?

Begin with the exact product name, manufacturer, current local product information and product-specific clinical evidence.

12. Conclusion

Korean botulinum toxin type A products should be evaluated individually rather than treated as one interchangeable category.

Neuronox and NABOTA illustrate this distinction. They have different manufacturers, product identities and clinical development programs.

Neuronox has randomized clinical evidence, including a Phase III comparison with onabotulinumtoxinA in glabellar lines. Daewoong's DWP450/prabotulinumtoxinA program also includes randomized comparative studies in glabellar lines. ［2,4,5］

An evidence-based evaluation should identify the exact product and jurisdiction, verify the applicable label, examine clinical trials by indication and endpoint, keep potency units product-specific, and preserve safety and disclosure information.

The relevant question is not simply where a botulinum toxin product was manufactured, but what the verified product information and clinical evidence establish about that specific preparation.

References

［1］ NEURONOX (Botulinum Toxin Type A). Thai product information. Revised April 3, 2023. Manufacturer: Medytox Inc., Republic of Korea.

［2］ Lee WS, et al. Efficacy and safety of a new botulinum toxin type A for glabellar lines: randomized, double-blind, active-controlled, multicenter phase III study. Dermatologic Surgery. 2013;39:171–178. doi:10.1111/dsu.12072.

［3］ Daewoong Pharmaceutical. NABOTA product information webpage. Botulinum toxin type A; product presentations and selected approved indications by market. Accessed September 2026.

［4］ Won CH, et al. Comparative trial of DWP450 versus onabotulinumtoxinA in glabellar lines: multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology. 2015;54:227–234. doi:10.1111/ijd.12627.

［5］ Rzany BJ, et al. A multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for moderate-to-severe glabellar lines. Aesthetic Surgery Journal. 2020;40:413–429. doi:10.1093/asj/sjz110.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.